Oral sustained release nystatin tablets for the treatment of oral candidiasis: Formulation development and validation of UV spectrophotometric analytical methodology for content determination

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 594-600

  De Aguiar, Michelle Maria Gonçalves Barão ^a   De Albuquerque, Raphael Pereira ^a   Marinho, Daniel Savignon ^a   Braga, Bàrbara Regina Souza ^b   Dornelas, Camila Braga ^c   Oliveira, Anderson ^d   De Sousa, Valéria Pereira ^a   Torres, Sandra Regina ^b   Alviano, Daniela Sales ^b   Alviano, Celuta Sales ^b   Cabral, Lúcio Mendes ^a   Holandino, Carla ^a  

^a Cidade Universitária RJ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^d Juiz de Forma   (Brazil)

Author keywords

Candidiasis; Clinical efficacy; Mucoadhesive; Nystatin; Oral sustained release tablets

Indexed keywords

NYSTATIN;

ABSORPTION SPECTROPHOTOMETRY; AQUEOUS SOLUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; HUMAN; MECHANICAL STIMULATION; MOUTH CAVITY; MUCOADHESION; PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SUSPENSION; SUSTAINED DRUG RELEASE; TABLET PROPERTY; TASTE; THRUSH; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION PROCESS;

ADMINISTRATION, ORAL; CANDIDIASIS, ORAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; MOUTH MUCOSA; NYSTATIN; PILOT PROJECTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; TREATMENT OUTCOME;

EID: 77952660647     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903384729     Document Type: Article

References (33)

1. Tommasi AF. (1998). Diagnóstico em Patologia Bucal. In: Pancast, ed., p. 196, 197, 202. São Paulo.
2. Neville BW, Damm DD, Allen CM, Bouquot JE. (1998). Patologia Oral & Maxilofacial. In: Guanabara-Koogan (Ed.), (pp. 176-204, 190, 700). Rio de Janeiro.
3. Menezes EA, Sá KM, Cunha FA., Ângelo M R F, Oliveira I R N, Salviano M N C. (2005). Freqüência e atividade enzimática de Candida albicans isoladas da mucosa bucal de crianças de uma creche da prefeitura de Fortaleza. J Bras Patol Med Lab, 43 (3): 9-13.
4. Leigh JE, Shetty K, Fidel PL. Jr. (2004). Oral opportunistic infections in HIV-positive individuals: review and role of mucosal immunity. AIDS Patients Care STDs, 18 (8): 443-56.
5. Akpan A, Morgan R. (2002). Oral Candidiasis. Postgraduate Med J, 78: 455-459.
6. Ship J, Vissink A, Challacombe S. (2007). Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103: S6.e1-S6.e14.
7. Ellepola A N B, Samaranyake, LP. (2000). Antimycotics agents in oral candidosis: an overview. Crit Review Oral Biol Med, 11: 172-198.
8. Tavares W. (2001). Manual de Antibióticos e Quimioterápicos Antiinfecciosos. In: Atheneu, ed., p. 20-21, 747-749, 758-759. Rio de Janeiro.
9. Gilman AG., Hardman JG, Limbird LE. (2003). As Bases Farmacoló gicas da Terapêutica. In: McGraw-Hill Interamericana do Brasil, ed., (pp. 413, 867, 971-972, 982). Rio de Janeiro, Brasil.
10. Eptein JB, Polsky, B. (1998). Orapharyngeal candidiasis: a review of its clinical sprectrum and current therapies. Clin Ther, 20 (1): 40-57.
11. Farah CS, Ashman RB, Challacombe, SJ. (2000). Oral candidosis. Clin Dermatol, 18 (5): 553-562.
12. Patton LL, Bonito AJ, Shugars DA. (2001). A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 92 (2): 170-179.
13. Sidrim J J C, Moreira J L B. (2004). Micologia Médica à Luz dos Autores Contemporâneos. In: Guanabara Koogan, ed., Rio de Janeiro.
14. Baccaglini L, Atkinson JC, Patton LL, Glick M, Ficarra G, Peterson DE. (2007). Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103 (Suppl. S50): e1-e23.
15. Groeschke J, Solassol I, Bressolle F, Pinguet F. (2006). Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate. J Pharm Biom Anal, 42: 362-366.
16. Hac-Wydro K, Dynarowicz-Latka P. (2006a). Interation between nystatin and natural membrane lipids in Lagmuir monolayers-the role of a phospholipids in the mechanism of polyenes mode of action. Biophys Chem, 123: 154-161.
17. Hac-Wydro K, Dynarowicz-Latka P. (2006b). Nystatin in Langmiur monolayres at the air/water interface. Colloids Surf B Biointerfaces, 53: 64-71.
18. Casiglia JW, Woo S. (2000). Oral manifestations of HIV infection. Clin Dermatol, 18: 541-551.
19. Dorocka-Bobkowska B, Konopka K, Düzgünes, N. (2003). Influence of antifungical polyenes on the adhesion of Candida albicans and Candida glabrata to human epithelial cells in vitro. Arch Oral Biol, 48 (12): 805-814.
20. Silva L, Coutinho A, Fedorova A, Prieto M. (2006). Nystatininduced lipid vesicles permeabilization is strongly dependent of sterol structure. Bioch Biophys Acta, 1758 (4), 452-459.
21. Croy SR, Known, GS. (2004). The effects of Pluronic block aggregation state of nystatin. J Control Rel, 95 (2): 161-171.
22. Codd JE, Deasy PB. (1998). Formulation and development and in vivo evaluation of a novel bioadhesive lozenge containing a synergistic combination of antifungal agensts. Int J Pharmacol, 173: 13-24.
23. Gupta VK, Hariharan M, Wheatley TA, Price JC. (2001). Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors. Eur J Pharm Biopharm, 51: 241-248.
24. United States Pharmacopeia (2008). In: Rockville, ed., The United States Pharmacopeial Convention, p. 103-109, 630, 2786.
25. Brazilian Pharmacopoeia (1998). 4th ed. São Paulo, Brasil: Atheneu Editora.
26. ICH Topic Q2B Note for Guidance on Validation of Analytical Procedures: Methodology GPMP/ICH/28 1/95. (1996).
27. Martindale: The Complete Drug Reference. (1999). 32th ed. In London Pharmaceutical Press, ed., 386 p.
28. Aksungur P, Sungur A, Unal S, Iskit AB, Squier CA, Senel S. (2004). Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. J Control Rel, 98 (2): 269-279.
29. Llabot JM, Manzo RH, Allemandi DA. (2003). Double-layered mucoadhesive tablets containing nystatin. AAPS Pharm Sci Tech, 3: 1-6.
30. Llabot JM., Manzo RH, Allemandi DA. (2004). Drug release from carbomer: carbomer sodium matrices with potencial use as mucoadhesive drug delivrey system. Int J Pharm, 276: 59-66.
31. Cappello B, De Rosa G, Giannini L, La Rotonda MI, Mensitieri G, Miro A, et al. (2006). Cyclodextrin-containing poly (ethylenooxide) tablets for the delivery of poorly soluble drugs: potencial as buccal delivery system. Int J Pharmacol, 319: 79-85.
32. Lubbers S, Guichard E. (2003). The effects of sugars and pectin on flavour release from a fruit pastilles model system. Food Chem, 81: 269-273.
33. Azarmi S, Roa W, Löbenberg R. (2006). Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharmaceut, 328 (1): 12-21.